Combined Genetic Defect (Homogeneity for Factor V Leiden and Heterogeneity for Prothrombin G20210A Allele),in a Young Patient,with Recurrent Deep Vein Thrombosis and Serious Postphlebitic Syndrome

Abstract

Just a few years ago, resistance to activated protein C (APCR) was reported to be of high significance representing a strong predisposing factor in the development of venous thrombosis (VT). A little while later, APCR was established to be the result of a point mutation of the factor V gene (factor V Leiden: a G-to-A transition at position 1691). Up to today, it is not certain whether factor V Leiden is in itself able to lead to VT, or whether it acts in synergy with other factors. Nevertheless, heterozygous subjects have a tenfold increase in the risk of VT when compared to general population, whereas the risk is 80 times greater in homozygous individuals. In 1996, a prothrombin gene mutation (prothrombin G20210A allele), which is a single-nucleotide G-to-A transition at position 20210 in the sequence of the 3'-untranslated region (3'UTR) on chromosome 11, was discovered. The presence of this mutant gene results in elevated plasma prothrombin concentrations, increasing the possibility for the development of VT. However, the coex- istence of these two abnormalities, as well as the clinical consequence, have not yet been studied. So far, only a few reports are found in the literature describing the coexistence of both mutations. The authors present a 25-year-old patient with a simultaneous double mutation of the FV and F II gene. The patient was homozygous for the factor V Leiden and heterozygous for the prothrombin G20210A allele. It is unclear whether the coexis tence of the two predisposes more to the development of VT than the summation of the two as independent factors.

Get full access to this article

View all access options for this article.

References

Bertina MR : Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 43:1678-1683, 1997 .

Dahlback B. : Factor V gene mutation causing inherited resistance to activated C as a basis for venous thromboembolism. J Intern Med 237:221-227, 1995.

Adams GJ Jr, Silver D. : Deep venous thrombosis and pulmonary embolism—risk factors. In: Current Diagnosis and Treatment in Vascular Surgery, ed. by Dean HR , Yao STJ , Brewster CD. East Norwalk: Appleton & Lang publications, 1995, pp 337-380.

Bertina RM , Koeleman Bpc , Koster T. , et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67, 1994.

Poort SR , Rosendaal FR , Reitsma PH , et al: A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-3703, 1996.

Makris M. , Preston FE , Beauchamp NJ , et al: Coinheritance of the 20210 allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 78 :1426-1429, 1997.

Alhenc-Gelas M. , Le Camp-Duchez V. , Emmerich J. , et al: The A20210 allele of the prothrombin gene is not frequently associated with the factor V Arg 506 to Gin mutation in thrombophilic families. Blood 90: 1711, 1997.

Zoller B. , Svensson PJ , Dahlback B. , et al: Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated Protein C. J Clin Invest 94: 2521-2524, 1994 .

Arruda VR , Annichino-Bizzachi JM , Goncalves MS , et al: Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Hemost 78:1430-1433, 1997.

10.

Rosendaal FR : Risk factors for venous thrombosis: Prevalence, risk and interaction. Semin Hemat 34:171-187, 1997.

11.

Dahlback B. , Carlsson M. , Svensson PJ : Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Prediction of an anticoagulant response to activated protein C . Proc Natl Acad Sci USA 90:1004-1008, 1993 .

12.

Koster T. , Rosendaal FR , Briet E. , et al: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342: 1503-1506, 1993.

13.

Rees CD , Cox M. , Clegg BJ : World distribution of factor V Leiden. Lancet 346:1133-1134, 1995.

14.

Mitsis M. , Eleftheriou A. , Ioannou H. , et al: Genetic defects of factors II and V in the general population and in patients with venous thrombosis. Sixth Greek Congress of Angiology and Vascular Surgery. Athens Jan 22-24, 1999, abstract book, p 83.

15.

Bontempo AF , Hassett CA , Faruki H. , et al: The factor V Leiden mutation: Spectrum of thrombotic events and laboratory evaluation. J Vasc Surg 25:271-276, 1997.

16.

Souto JC , Coll I. , Llobet D. , et al: The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 80:366-369, 1998.

17.

Brown K. , Luddington R. , Williamson D. , et al: Risk of venous thromboembolism associated with a G-to-A transition at position 20210 in the 3'-untranslated region of the prothrombin gene. Br J Haematol 98: 907-909, 1997.

18.

Hillarp A. , Zoller B. , Svensson PJ , et al: The 20210A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 78:990-992, 1997.